You are viewing the site in preview mode
Skip to main content
| |
Excluded from randomized controlled trial (N = 295)
|
Included in randomized controlled trial (N = 406)
|
P value
|
|---|
|
Infection characteristics
|
|
Acquisition of infection in the intensive care unit
|
67 (22.7%)
|
124 (30.5%)
|
0.022
|
|
Pathogen
|
|
Acinetobacter baumannii
|
236 (80%)
|
312 (76.8%)
|
0.318
|
|
Enterobacterales
|
35 (11.9%)
|
73 (18%)
|
0.027
|
|
Pseudomonas/other
|
24 (8.1%)
|
21 (5.2%)
|
0.114
|
|
Type of infection
|
|
Bacteraemia
|
109 (36.9%)
|
173 (42.6%)
|
0.131
|
|
Ventilator-associated or hospital-acquired pneumonia
|
140 (47.5%)
|
182 (44.8%)
|
0.490
|
|
Probable ventilator-associated pneumonia
|
14 (4.7%)
|
25 (6.2%)
|
0.421
|
|
Urinary tract infection
|
32 (10.8%)
|
26 (6.4%)
|
0.035
|
|
Colistin MIC distribution > 0.5 mg/L
|
18 (7.7%), n = 233
|
85 (24.3%), n = 350
|
0.000
|
|
Antibiotic treatment
| | |
0.000
|
|
Colistin
|
113 (68.1%), n = 166
|
198 (48.8%)
| |
|
Colistin and meropenem
|
53 (31.9%), n = 166
|
208 (51.2%)
| |
|
Colistin loading dose
|
122 (73.5%), n = 166
|
376 (92.6%)
|
0.000
|
|
Treatment days in patients alive ≥14 days, median (Percentiles 25–75)
|
8.5 (0–15), n = 200
|
13 (10–16), n = 273
|
0.000
|
|
Mean colistin maintenance dose per day, million units (percentiles 25–75)
|
|
Creatinine clearance< 50 ml/min
|
4.2 (2.1–6.0)
|
4.0 (3.0–6.0)
|
0.629
|
|
Creatinine clearance≥50 ml/min
|
8.6 (5.8–9.0)
|
8.5 (7.0–9.0)
|
0.239
|
- aNumbers apply to all patients in the group unless stated otherwise
